AU784589B2 - Bryostatin analogues, synthetic methods and uses - Google Patents

Bryostatin analogues, synthetic methods and uses Download PDF

Info

Publication number
AU784589B2
AU784589B2 AU19440/01A AU1944001A AU784589B2 AU 784589 B2 AU784589 B2 AU 784589B2 AU 19440/01 A AU19440/01 A AU 19440/01A AU 1944001 A AU1944001 A AU 1944001A AU 784589 B2 AU784589 B2 AU 784589B2
Authority
AU
Australia
Prior art keywords
compound
formula
mmol
etoac
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19440/01A
Other languages
English (en)
Other versions
AU1944001A (en
Inventor
Kevin W. Hinkle
Blaise Lippa
Cheol-Min Park
Paul A. Wender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU1944001A publication Critical patent/AU1944001A/en
Application granted granted Critical
Publication of AU784589B2 publication Critical patent/AU784589B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU19440/01A 1999-11-30 2000-11-30 Bryostatin analogues, synthetic methods and uses Ceased AU784589B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16818199P 1999-11-30 1999-11-30
US60/168181 1999-11-30
PCT/US2000/032896 WO2001040214A1 (en) 1999-11-30 2000-11-30 Bryostatin analogues, synthetic methods and uses

Publications (2)

Publication Number Publication Date
AU1944001A AU1944001A (en) 2001-06-12
AU784589B2 true AU784589B2 (en) 2006-05-04

Family

ID=22610449

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19440/01A Ceased AU784589B2 (en) 1999-11-30 2000-11-30 Bryostatin analogues, synthetic methods and uses

Country Status (6)

Country Link
US (1) US6624189B2 (enExample)
EP (1) EP1233956A4 (enExample)
JP (1) JP2003515601A (enExample)
AU (1) AU784589B2 (enExample)
CA (1) CA2393026A1 (enExample)
WO (1) WO2001040214A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US7232842B2 (en) * 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
CA2516393A1 (en) * 2003-02-20 2004-09-02 Board Of Regents, University Of Texas System Synthesis of peloruside a and analogs thereof for use as antitumor agents
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US20070026488A1 (en) * 2005-07-27 2007-02-01 Targett Nancy M Biosynthesis of bryostatins by polyketide synthases (PKS)
US20070054890A1 (en) 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
JP4710698B2 (ja) * 2006-04-10 2011-06-29 宇部興産株式会社 シリルエーテル基を有するβ−ジケトン化合物の製造法
US20080058396A1 (en) * 2006-07-28 2008-03-06 Alkon Daniel L Methods of stimulating cellular growth, synaptic remodelling and consolidation of long-term memory
CA2659242C (en) 2006-07-28 2015-08-11 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
KR20140049054A (ko) * 2007-02-09 2014-04-24 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 두부 외상으로 유발된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과
US8497385B2 (en) * 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US20100280262A1 (en) 2007-10-19 2010-11-04 Wender Paul A Bryostatin analogues, synthetic methods and uses
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US9107890B2 (en) 2010-07-08 2015-08-18 Blanchette Rockefeller Neurosciences Institute PKC activators and anticoagulant in regimen for treating stroke
CA2808660A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
JP6422778B2 (ja) 2011-11-13 2018-11-14 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｐｋｃアクチベーターおよびその組合せ
US9163032B2 (en) 2011-11-13 2015-10-20 Blanchette Rockefeller Neurosciences Insitute Esters of DCPLA and methods of treatment using the same
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
US9816066B2 (en) 2012-04-24 2017-11-14 The Regents Of The University Of California Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
CN109331013B (zh) * 2012-11-27 2022-02-01 阿菲欧斯公司 苔藓素组合物、其制备方法和用途
HK1218882A1 (zh) 2012-11-28 2017-03-17 Aphios Corporation 用於治疗神经退化疾病和其它疾病的组合治疗剂和方法
JP2016516201A (ja) 2013-03-15 2016-06-02 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 神経保護性ｐｋｃ活性化因子を特定する方法
KR20170031653A (ko) 2014-04-18 2017-03-21 뉴로트롭 바이오싸이언스 인크. 지질 축적 장애의 치료를 위한 방법 및 조성물
JP2018521113A (ja) 2015-05-11 2018-08-02 アルコン、ダニエル・エル． ＡｐｏＥ４対立遺伝子の存在を決定した後のＰＫＣ活性化因子を使用した神経変性状態の治療
WO2017053659A1 (en) 2015-09-23 2017-03-30 Khan Tapan K Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
WO2017062924A1 (en) 2015-10-08 2017-04-13 Alkon Daniel L Dosing regimens of pkc activators
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
JP7148147B2 (ja) 2016-10-05 2022-10-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ブリオスタチン化合物およびその調製方法
AU2018246378A1 (en) 2017-03-31 2019-10-17 Cellectis Sa New universal chimeric antigen receptor T cells specific for CD22
WO2018187647A1 (en) 2017-04-06 2018-10-11 Neurotrope Bioscience, Inc. Methods and compositions for treatment of neurological diseases, disorders, or conditions
EP3964210A1 (en) 2018-05-18 2022-03-09 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease
US20220133687A1 (en) * 2020-11-02 2022-05-05 Synaptogenix, Inc. Methods of treating and preventing neurodegenerative diseases with hgf activating compounds
AU2021386370A1 (en) 2020-11-24 2023-06-22 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
CN113773256B (zh) * 2021-09-16 2022-11-18 精华制药集团南通有限公司 一种琥布宗的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
AU2337997A (en) 1996-03-20 1997-10-10 Arizona Board Of Regents, The Method of treating cancer using c-26 modified bryostatin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones

Also Published As

Publication number Publication date
WO2001040214A1 (en) 2001-06-07
US6624189B2 (en) 2003-09-23
JP2003515601A (ja) 2003-05-07
CA2393026A1 (en) 2001-06-07
AU1944001A (en) 2001-06-12
EP1233956A4 (en) 2006-07-05
US20020137789A1 (en) 2002-09-26
EP1233956A1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
US6624189B2 (en) Byrostatin analogues, synthetic methods and uses
US7256286B2 (en) Bryostatin analogues, synthetic methods and uses
US8497385B2 (en) Bryostatin analogues, synthetic methods and uses
Zurwerra et al. Total synthesis of (−)‐zampanolide and structure–activity relationship studies on (−)‐dactylolide derivatives
JP3360186B2 (ja) ６，７位を修飾したパクリタキセル類
US6096909A (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
CN101899026A (zh) 用于制备软海绵素b的中间体
AU2003215821A1 (en) Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof
US9096550B2 (en) Bryostatin analogues and methods of making and using thereof
EP1669358A1 (en) Cytotoxic agents comprising new taxanes
US5739359A (en) Methods for preparing 1-deoxy paclitaxels
EP1688415A1 (en) Cytotoxic agents comprising new C-2 modified taxanes
US5773464A (en) C-10 epoxy taxanes
US20030134883A1 (en) 14-Methyl-epothilones
EP1581218A1 (en) Epothilone analogs for site specific delivery in the treatment of proliferative diseases
US8735609B2 (en) Bryostatin analogues, synthetic methods and uses
US20170239212A1 (en) Bryostatin analogs and use thereof as antiviral agents
US7776849B2 (en) Benzenoid ansamycin derivative
US20020022651A1 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
WO2003070719A1 (en) Bryostatin analogues, synthetic methods and uses
US20090163563A1 (en) Phorboxazole Compounds and Methods of Their Preparation
Canetero et al. New approach to the stereoselective synthesis of the [4.5] spiroketal moiety of papulacandins
WO1999032109A1 (en) 7-deoxy-6-nitrogen substituted paclitaxels
RU2419622C2 (ru) Производные таксола с противоопухолевой активностью
KR20040030926A (ko) 항종양제로서 사용하는 파크리탁셀의 ｃ-2'메틸화된 유도체